Evidence map›Paper›PMID 33523875›Full record

ArticleScience advances2021

Induction of muscle-regenerative multipotent stem cells from human adipocytes by PDGF-AB and 5-azacytidine.

Avani Yeola, Shruthi Subramanian, Rema A Oliver, Christine A Lucas, Julie A I Thoms, Feng Yan, Jake Olivier, Diego Chacon, Melinda L Tursky, Pallavi Srivastava and 17 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 11 institutions in 2 countries.

Avani YeolaAdult Cancer Program, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia.ORCID 0000-0003-4210-1371
Shruthi SubramanianAdult Cancer Program, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia.ORCID 0000-0003-3426-0356
Rema A OliverSurgical and Orthopaedic Research Laboratories, Prince of Wales Clinical School, UNSW Sydney, Sydney, NSW 2052, Australia.ORCID 0000-0002-2381-7326
Christine A LucasCellular and Genetic Medicine Unit, School of Medical Sciences, UNSW Sydney, Sydney, NSW 2052, Australia.
Julie A I ThomsAdult Cancer Program, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia.ORCID 0000-0002-4876-7230
Feng YanAustralian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-8848-1739
Jake OlivierSchool of Mathematics and Statistics, UNSW Sydney, Sydney, NSW 2052, Australia.ORCID 0000-0002-3144-4507
Diego ChaconSchool of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia.
Melinda L TurskySt. Vincent's Centre for Applied Medical Research, St Vincent's Hospital Sydney and St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2010, Australia.
Pallavi SrivastavaSchool of Material Sciences and Engineering, School of Chemistry, Australian Centre for Nanomedicine, UNSW Sydney, Sydney, NSW 2052, Australia.ORCID 0000-0003-4322-2466
Jason R PotasTranslational Neuroscience Facility, School of Medical Sciences, UNSW Sydney, Sydney, NSW 2052, Australia.ORCID 0000-0002-1973-8211
Tzongtyng HungBiological Resources Imaging Laboratory, Mark Wainwright Analytical Centre, UNSW Sydney, Sydney, NSW 2052, Australia.ORCID 0000-0002-2904-2664
Carl PowerBiological Resources Imaging Laboratory, Mark Wainwright Analytical Centre, UNSW Sydney, Sydney, NSW 2052, Australia.
Philip HardyCyto Labs, Bentley, WA 6102, Australia.
David D MaSt. Vincent's Centre for Applied Medical Research, St Vincent's Hospital Sydney and St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2010, Australia.
Kristopher A KilianSchool of Material Sciences and Engineering, School of Chemistry, Australian Centre for Nanomedicine, UNSW Sydney, Sydney, NSW 2052, Australia.ORCID 0000-0002-8963-9796
Joshua McCarrollChildren's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales Sydney, Sydney, NSW, Australia.ORCID 0000-0001-8807-3623
Maria KavallarisChildren's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales Sydney, Sydney, NSW, Australia.ORCID 0000-0003-2309-898X
Luke B HessonPrince of Wales Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2052, Australia.
Dominik BeckSchool of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia.
David J CurtisAustralian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia.ORCID 0000-0001-9497-0996
Jason W H WongSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region.
Edna C HardemanCellular and Genetic Medicine Unit, School of Medical Sciences, UNSW Sydney, Sydney, NSW 2052, Australia.ORCID 0000-0003-1649-7712
William R WalshSurgical and Orthopaedic Research Laboratories, Prince of Wales Clinical School, UNSW Sydney, Sydney, NSW 2052, Australia.ORCID 0000-0002-5023-6148
Ralph MobbsSurgical and Orthopaedic Research Laboratories, Prince of Wales Clinical School, UNSW Sydney, Sydney, NSW 2052, Australia.
Vashe ChandrakanthanAdult Cancer Program, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia. v.chandrakanthan@unsw.edu.au jpimanda@unsw.edu.au.ORCID 0000-0002-4314-5029
John E PimandaAdult Cancer Program, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia. v.chandrakanthan@unsw.edu.au jpimanda@unsw.edu.au.ORCID 0000-0002-0509-8962
Cancer Institute of New South Wales · AUUNSW Sydney · AUPrince of Wales Hospital · AUARC Centre of Excellence in Advanced Molecular Imaging · AUSt Vincent's Hospital Sydney · AUUniversity of Technology Sydney · AUAlfred Health · AUCyto Labs · AUGarvan Institute of Medical Research · AUMonash University · AUUniversity of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Terminally differentiated murine osteocytes and adipocytes can be reprogrammed using platelet-derived growth factor-AB and 5-azacytidine into multipotent stem cells with stromal cell characteristics. We have now optimized culture conditions to reprogram human adipocytes into induced multipotent stem (iMS) cells and characterized their molecular and functional properties. Although the basal transcriptomes of adipocyte-derived iMS cells and adipose tissue-derived mesenchymal stem cells were similar, there were changes in histone modifications and CpG methylation at cis-regulatory regions consistent with an epigenetic landscape that was primed for tissue development and differentiation. In a non-specific tissue injury xenograft model, iMS cells contributed directly to muscle, bone, cartilage, and blood vessels, with no evidence of teratogenic potential. In a cardiotoxin muscle injury model, iMS cells contributed specifically to satellite cells and myofibers without ectopic tissue formation. Together, human adipocyte-derived iMS cells regenerate tissues in a context-dependent manner without ectopic or neoplastic growth.

Indexed as

AzacitidinePlatelet-Derived Growth FactorAdipocytesAdipose TissueAnimalsCell DifferentiationCells, CulturedHumansMiceMultipotent Stem CellsMusclesAzacitidinePlatelet-Derived Growth Factorplatelet-derived growth factor AB

Identifiers

PMID33523875
PMCPMC7806226
OpenAlexW3120341478

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.